[1]唐 文,陈爱军.银屑病相关肾脏损害的发病机制[J].医学信息,2021,34(06):36-39.[doi:10.3969/j.issn.1006-1959.2021.06.010]
 TANG Wen,CHEN Ai-jun.Pathogenesis of Psoriasis-related Kidney Damage[J].Medical Information,2021,34(06):36-39.[doi:10.3969/j.issn.1006-1959.2021.06.010]
点击复制

银屑病相关肾脏损害的发病机制()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年06期
页码:
36-39
栏目:
综述
出版日期:
2021-03-15

文章信息/Info

Title:
Pathogenesis of Psoriasis-related Kidney Damage
文章编号:
1006-1959(2021)06-0036-04
作者:
唐 文陈爱军
(重庆医科大学附属第一医院皮肤科,重庆 400016)
Author(s):
TANG WenCHEN Ai-jun
(Department of Dermatology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
关键词:
银屑病肾脏损害炎症反应及细胞因子氧化应激
Keywords:
PsoriasisKidney damageInflammation and cytokinesOxidative stress
分类号:
R692
DOI:
10.3969/j.issn.1006-1959.2021.06.010
文献标志码:
A
摘要:
银屑病被认为是一种免疫介导的慢性炎症性疾病,常累及皮肤和关节,目前已阐明其与糖尿病、高血压、代谢综合征、动脉粥样硬化等多种共存疾病有关。近年来国内外多个研究发现银屑病是慢性肾脏病和终末期肾病的独立危险因素,并提出“银屑病肾病”这一概念,银屑病本身及其治疗药物引起的肾脏损害备受关注,相关肾脏损害与炎症反应、氧化应激、免疫复合物沉积、肾素-血管紧张素-醛固酮系统过度激活、内皮功能障碍、胰岛素抵抗、脂肪因子紊乱、遗传和药物等因素有关。本文就银屑病相关肾脏损害的发病机制做一综述。
Abstract:
Psoriasis is considered to be an immune-mediated chronic inflammatory disease that often affects the skin and joints. It has been clarified that it is related to multiple coexisting diseases such as diabetes, hypertension, metabolic syndrome, and atherosclerosis.In recent years, many domestic and foreign studies have found that psoriasis is an independent risk factor for chronic kidney disease and end-stage renal disease, and proposed the concept of "psoriatic nephropathy".Kidney damage caused by psoriasis itself and its treatment drugs has attracted much attention. Related kidney damage and inflammation, oxidative stress, immune complex deposition,the renin-angiotensin-aldosterone system is over-activated, endothelial dysfunction, insulin resistance, adipokines disorders, genetics and drugs.This article reviews the pathogenesis of psoriasis-related kidney damage.

参考文献/References:

[1]Lee E,Han JH,Bang CH,et al.Risk of End-Stage Renal Disease in Psoriatic Patients:Real-World Data from a Nationwide Population-Based Cohort Study[J].Sci Rep,2019,9(1):16581. [2]Shah K,Mellars L,ChangolkarA,et al.Real-world burden of comorbidities in US patients with psoriasis[J].J Am Acad Dermatol,2017,77(2):287-292. [3]Singh NP,Prakash A,Kubba S,et al.Psoriatic nephropathy-does an entity exist[J].Ren Fail, 2005,27(1):123-127. [4]Chiu HY,Huang HL,Li CH,et al.Increased risk of glomerulonephritis and chronic kidney disease in relation to the severity of psoriasis,concomitant medication,and comorbidity:a nationwide population-based cohort study[J].Br J Dermatol,2015,173(1):146-154. [5]Ungprasert P,Raksasuk S.Psoriasis and risk of incident chronic kidney disease and end-stage renal disease:a systematic review and meta-analysis[J].Int Urol Nephrol,2018,50(7):1277-1283. [6]Ren F,Zhang M,Zhang C,et al.Psoriasis-Like Inflammation Induced Renal Dysfunction Through the TLR/NF-κ B Signal Pathway[J].Biomed Res Int,2020(2020):3535264. [7]Li S,Liu Y,He Y,et al.Podocytes present antigen to activate specific T cell immune responses in inflammatory renal disease[J].J Pathol,2020,252(2):165-177. [8]Al-Harbi NO,Nadeem A,Ansari MA,et al.Psoriasis-like inflammation leads to renal dysfunction via upregulation of NADPH oxidases and inducible nitric oxide synthase[J]. IntImmunopharmacol,2017(46):1-8. [9]Podkowińska A,Formanowicz D.Chronic Kidney Disease as Oxidative Stress-and Inflammatory-Mediated Cardiovascular Disease[J].Antioxidants (Basel),2020,9(8):752. [10]Thomas J,Küpper M,Batra R, et al.Is the humoral immunity dispensable for the pathogenesis of psoriasis[J].J Eur Acad Dermatol Venereol,2019,33(1):115-122. [11]Grewal SK,Wan J,Denburg MR,et al.The risk of IgA nephropathy and glomerular disease in patients with psoriasis:a population-based cohort study[J].Br J Dermatol,2017,176(5):1366-1369. [12]Magistroni R,D’Agati VD,Appel GB,et al.New developments in the genetics, pathogenesis,and therapy of IgA nephropathy[J].Kidney Int,2015,88(5):974-989. [13]Takeshita J,Wang S,Shin DB,et al.Effect of psoriasis severity on hypertension control:a population-based study in the United Kingdom[J].JAMA Dermatol,2015,151(2):161-169. [14]Koppe L,Fouque D.The Role for Protein Restriction in Addition to Renin-Angiotensin-Aldosterone System Inhibitors in the Management of CKD[J].Am J Kidney Dis,2019,73(2):248-257. [15]Alba BK,Greaney JL,Ferguson SB,et al.Endothelial function is impaired in the cutaneous microcirculation of adults with psoriasis through reductions in nitric oxide-dependent vasodilation[J].Am J Physiol Heart Circ Physiol,2018,314(2):H343-H349. [16]Garshick MS,Barrett TJ,Wechter T,et al.Inflammasome Signaling and Impaired Vascular Health in Psoriasis[J].Arterioscler Thromb Vasc Biol,2019,39(4):787-798. [17]李雪,解欣然,蒙玉娇,等.银屑病与胰岛素抵抗[J].环球中医药,2019,12(6):972-978. [18]Redon J,Lurbe E.The kidney in obesity[J].Curr Hypertens Rep,2015,17(6):555. [19]Wong Y,Nakamizo S,Tan KJ,et al.An Update on the Role of Adipose Tissues in Psoriasis[J]. Front Immunol,2019(10):1507. [20]Rutkowski JM,Wang ZV,Park AS,et al.Adiponectin promotes functional recovery after podocyte ablation[J].J Am Soc Nephrol,2013,24(2):268-282. [21]Dervisoglu E,Akturk AS,Yildiz K,et al.The spectrum of renal abnormalities in patients with psoriasis[J].Int Urol Nephrol,2012,44(2):509-514. [22]曹璐,张建江,席微波,等.儿童银屑病共病肾损害的临床研究[J].中国妇幼健康研究,2020,31(6):818-822. [23]Yan K,Zhang Y,Han L,et al.Safety and efficacy of methotrexate for Chinese adults with psoriasis with and without psoriatic arthritis[J].JAMA Dermatol,2019,155(3):327-334. [24]Kim BR,Yang S,Doh EJ,et al.Risk factors affecting adverse effects of cyclosporine A in a real-world psoriasis treatment[J].Ann Dermatol,2018,30(2):143-149. [25]Hong JR,Lee YW,Choe YB,et al.Risk factors for increased serum creatinine level in patients with psoriasis treated with cyclosporine in a real-world practice[J].Dermatol Ther,2019,32(3):e12875. [26]Dabak DO,Kocaman N.Effects of silymarin on methotrexate-induced nephrotoxicity in rats[J].Ren Fail,2015,37(4):734-739. [27]Heidari R,Ahmadi A,Mohammadi H,et al.Mitochondrial dysfunction and oxidative stress are involved in the mechanism of methotrexate-induced renal injury and electrolytes imbalance[J].Biomed Pharmacother,2018(107):834-840. [28]Shalaby YM,Menze ET,Azab SS,et al.Involvement of Nrf2/HO-1 antioxidant signaling and NF-κB inflammatory response in the potential protective effects of vincamine against methotrexate-induced nephrotoxicity in rats:cross talk between nephrotoxicity and neurotoxicity[J].Arch Toxicol,2019,93(5):1417-1431. [29]CabelloZurita C,Grau Pérez M,Hernández Fernández CP,et al.Effectiveness and safety of Methotrexate in psoriasis:an eight-year experience with 218 patients[J].J Dermatolog Treat,2017,28(5):401-405. [30]Baker M,Perazella MA.NSAIDs in CKD:Are They Safe[J].Am J Kidney Dis,2020,76(4):546-557. [31]Maghfour J,Elliott E,Gill F,et al.Effect of biologic drugs on renal function in psoriasis patients with chronic kidney disease[J].J Am Acad Dermatol,2020,82(5):1249-1251. [32]Visconti L,Leonardi G,Buemi M,et al.Kidney disease and psoriasis: novel evidences beyond old concepts[J].Clin Rheumatol,2016,35(2):297-302. [33]Corden E,Higgins E,Smith C.Hypercalcaemia-induced kidney injury caused by the vitamin D analogue calcitriol for psoriasis:a note of caution when prescribing topical treatment[J].Clin Exp Dermatol,2016,41(8):899-901. [34]Ohigashi S,Tatsuno I,Uchida D,et al.Topical treatment with 22-oxacalcitriol(OCT),a new vitamin D analogue,caused severe hypercalcemia with exacerbation of chronic renal failure in a psoriatic patient with diabetic nephropathy;a case report and analysis of the potential for hypercalcemia[J].Intern Med,2003,42(12):1202-1205. [35]Braun G,Witt M,Mayer V,et al.Hypercalcemia caused by vitamin D3 analogs in psoriasis treatment[J].IntJ Dermatol,2007,46(12):1315-1317.

相似文献/References:

[1]郑文新,刘 红,汪 伟.银屑病易感基因的生物信息分析[J].医学信息,2018,31(21):1.[doi:10.3969/j.issn.1006-1959.2018.21.001]
 ZHENG Wen-Xin,LIU Hong,WANG Wei.Bioinformatics Analysis of the Susceptible Genes of Psoriasis[J].Medical Information,2018,31(06):1.[doi:10.3969/j.issn.1006-1959.2018.21.001]
[2]赵海莲.血尿酸水平与2型糖尿病肾病患者肾脏损害的相关性分析[J].医学信息,2020,33(06):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
 ZHAO Hai-lian.Correlation Between Serum Uric Acid Level and Renal Damage in Patients with Type 2 Diabetic Nephropathy[J].Medical Information,2020,33(06):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
[3]李小智,丁长松,黄辛迪.基于数据挖掘的中医治疗银屑病临床用药规律研究[J].医学信息,2021,34(01):4.[doi:10.3969/j.issn.1006-1959.2021.01.002]
 LI Xiao-zhi,DING Chang-song,HUANG Xin-di.Research on the Law of Clinical Use of Traditional Chinese Medicine for Psoriasis Based on Data Mining[J].Medical Information,2021,34(06):4.[doi:10.3969/j.issn.1006-1959.2021.01.002]
[4]熊戌霞,蔡梦珊,吴文钦.血清鳞状细胞癌抗原在常见皮肤病中的检测价值[J].医学信息,2021,34(17):181.[doi:10.3969/j.issn.1006-1959.2021.17.050]
 XIONG Xu-xia,CAI Meng-shan,WU Wen-qin.The Value of Serum Squamous Cell Carcinoma Antigen Detection in Common Skin Diseases[J].Medical Information,2021,34(06):181.[doi:10.3969/j.issn.1006-1959.2021.17.050]
[5]谢 晗,曾同祥.IL-17在常见皮肤病中的作用[J].医学信息,2021,34(23):33.[doi:10.3969/j.issn.1006-1959.2021.23.009]
 XIE han,ZENG Tong-xiang.Role of IL-17 in Common Skin Diseases[J].Medical Information,2021,34(06):33.[doi:10.3969/j.issn.1006-1959.2021.23.009]
[6]任静静,石 瑛,智艳芳,等.基于生物信息学分析筛选银屑病的关键基因[J].医学信息,2022,35(24):1.[doi:10.3969/j.issn.1006-1959.2022.24.001]
 REN Jing-jing,SHI Ying,ZHI Yan-fang,et al.Screening of Key Genes in Psoriasis Based on Bioinformatics Analysis[J].Medical Information,2022,35(06):1.[doi:10.3969/j.issn.1006-1959.2022.24.001]
[7]吴思琪,吕 健,席俊羽,等.冰黄肤乐软膏治疗银屑病的有效性和安全性的Meta分析[J].医学信息,2023,36(11):43.[doi:10.3969/j.issn.1006-1959.2023.11.008]
 WU Si-qi,LYU Jian,XI Jun-yu,et al.Meta-analysis of the Efficacy and Safety of Binghuang Fule Ointment in the Treatment of Psoriasis[J].Medical Information,2023,36(06):43.[doi:10.3969/j.issn.1006-1959.2023.11.008]
[8]黄 永,顾礼忠.NB-UVB与白芍总苷胶囊联合用于银屑病患者治疗对免疫功能及皮损PASI评分的影响[J].医学信息,2023,36(12):148.[doi:10.3969/j.issn.1006-1959.2023.12.030]
 HUANG Yong,GU Li-zhong.Effect of NB-UVB Combined with Total Glucosides of Paeony Capsule on Immune Function and PASI Score of Psoriasis Patients[J].Medical Information,2023,36(06):148.[doi:10.3969/j.issn.1006-1959.2023.12.030]

更新日期/Last Update: 1900-01-01